清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

来曲唑 帕博西利布 医学 乳腺癌 雌激素受体 内科学 肿瘤科 泌尿科 癌症 转移性乳腺癌 三苯氧胺
作者
Stephen R.D. Johnston,Shannon Puhalla,Duncan A. Wheatley,Alistair E. Ring,Peter A. Barry,Chris Holcombe,Jean Francois Boileau,Louise Provencher,André Robidoux,Mothaffar Fahed Rimawi,Stuart McIntosh,Ibrahim A. Shalaby,Robert C. Stein,Michael P. Thirlwell,David I. Dolling,James P. Morden,Claire F. Snowdon,Sophie L. Perry,Chester Cornman,Leona M. Batten
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (3): 178-189 被引量:228
标识
DOI:10.1200/jco.18.01624
摘要

PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy. PATIENTS AND METHODS: Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.0 cm were randomly assigned 3:2:2:2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 weeks, then palbociclib plus letrozole to 14 weeks (B); palbociclib for 2 weeks, then palbociclib plus letrozole to 14 weeks (C); or palbociclib plus letrozole for 14 weeks. Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule. Core-cut biopsies were taken at baseline and 2 and 14 weeks. Coprimary end points for letrozole versus palbociclib plus letrozole groups (A v B + C + D) were change in Ki-67 (protein encoded by the MKI67 gene; immunohistochemistry) between baseline and 14 weeks and clinical response (ordinal and ultrasound) after 14 weeks. Complete cell-cycle arrest was defined as Ki-67 less than or equal to 2.7%. Apoptosis was characterized by cleaved poly (ADP-ribose) polymerase. RESULTS: Three hundred seven patients were recruited. Clinical response was not significantly different between palbociclib plus letrozole and letrozole groups ( P = .20; complete response + partial response, 54.3% v 49.5%), and progressive disease was 3.2% versus 5.4%, respectively. Median log-fold change in Ki-67 was greater with palbociclib plus letrozole compared with letrozole (-4.1 v -2.2; P < .001) in the 190 evaluable patients (61.9%), corresponding to a geometric mean change of -97.4% versus -88.5%. More patients on palbociclib plus letrozole achieved complete cell-cycle arrest (90% v 59%; P < .001). Median log-fold change (suppression) of cleaved poly (ADP-ribose) polymerase was greater with palbociclib plus letrozole versus letrozole (-0.80 v -0.42; P < .001). More patients had grade 3 or greater toxicity on palbociclib plus letrozole (49.8% v 17.0%; P < .001) mainly because of asymptomatic neutropenia. CONCLUSION: Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which was possibly related to a concurrent reduction in apoptosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淡然雅彤完成签到,获得积分10
3秒前
温柔的海秋完成签到,获得积分10
14秒前
胡萝卜完成签到,获得积分10
21秒前
强健的千柔完成签到,获得积分10
30秒前
懦弱的绿蝶完成签到,获得积分10
41秒前
闪闪小凡完成签到,获得积分10
1分钟前
Hello的应助被科研通管家采纳,获得10
1分钟前
包容大地完成签到,获得积分10
1分钟前
俊逸吐司完成签到 ,获得积分10
1分钟前
风吹麦浪的应助被时之王者采纳,获得10
1分钟前
优雅的树叶完成签到,获得积分10
1分钟前
昴星引路完成签到 ,获得积分10
2分钟前
含蓄的芝麻完成签到,获得积分10
2分钟前
2分钟前
STEAM完成签到,获得积分10
2分钟前
STEAM发布了新的文献求助20
2分钟前
Monica张完成签到 ,获得积分10
2分钟前
Aboo完成签到,获得积分10
2分钟前
尊敬康乃馨完成签到,获得积分10
2分钟前
乐乐的应助被STEAM采纳,获得10
2分钟前
紧张的幼蓉完成签到,获得积分10
3分钟前
3分钟前
3分钟前
文静飞松完成签到,获得积分10
3分钟前
修渊完成签到 ,获得积分10
4分钟前
温暖的大船完成签到,获得积分10
4分钟前
波爷完成签到,获得积分10
4分钟前
科研通AI6.3的应助被amiee采纳,获得10
4分钟前
lianxin完成签到 ,获得积分10
4分钟前
ABC完成签到 ,获得积分10
4分钟前
4分钟前
云彦完成签到,获得积分10
4分钟前
李木禾完成签到 ,获得积分10
5分钟前
耍酷的雨泽完成签到,获得积分10
5分钟前
arniu2008的应助被科研通管家采纳,获得80
5分钟前
5分钟前
5分钟前
5分钟前
打打的应助被科研通管家采纳,获得10
5分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577354
关于积分的说明 21852358
捐赠科研通 7788708
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560092
邀请新用户注册赠送积分活动 2482902